Comment on

• EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.

  Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, Einsele H, Goldschmidt H, Knop S, Li C, Mellqvist UH, McFadden I, Oprea C, Ross JA, Talpes M, Hydren JR, Ahlstrom JM, Kazandjian D, Weinhold N, Zhang R, Stetler-Stevenson M, Marti G, Devlin SM. Landgren O, et al. Blood. 2024 Jul 25;144(4):359-367. doi: 10.1182/blood.2024024371. Blood. 2024. PMID: 38768337 Free PMC article.